Skip to main content
SpringerLink
Log in
Book cover

Current Treatment of Retroperitoneal Sarcomas pp 21–32Cite as

The Complex Nature of Soft Tissue Sarcomas, Including Retroperitoneal Sarcomas

  • Chapter

  • 595 Accesses

Part of the book series: Updates in Surgery ((UPDATESSURG))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Grizzi F, Di Ieva A, Russo C et al (2006) Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model 3:37

    Article  PubMed  PubMed Central  Google Scholar 

  2. Widschwendter M, Jones A, Evans I et al; FORECEE (4C) Consortium (2018) Epigenomebased cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol 15(5):292–309

    PubMed  Google Scholar 

  3. Halcrow PW, Dancer M, Panteah M et al (2016) Molecular changes associated with tumor initiation and progression of soft tissue sarcomas: targeting the genome and epigenome. Prog Mol Biol Transl Sci 144:323–380

    Article  CAS  PubMed  Google Scholar 

  4. Strauss DC, Hayes AJ, Thomas JM (2011) Retroperitoneal tumours: review of management. Ann R Coll Surg Engl 93(4):275–280

    Article  PubMed  PubMed Central  Google Scholar 

  5. Porpiglia AS, Reddy SS, Farma JM (2016) Retroperitoneal sarcomas. Surg Clin North Am 96(5):993–1001

    Article  PubMed  Google Scholar 

  6. Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353(7):701–711

    Article  CAS  PubMed  Google Scholar 

  7. Soini Y (2016) Epigenetic and genetic changes in soft tissue sarcomas: a review. APMIS 124(11):925–934

    Article  PubMed  Google Scholar 

  8. Sigston EAW, Williams BRG (2017) An emergence framework of carcinogenesis. Front Oncol 7:198

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gérard C, Goldbeter A (2016) Dynamics of the mammalian cell cycle in physiological and pathological conditions. Wiley Interdiscip Rev Syst Biol Med 8(2):140–156

    Article  PubMed  Google Scholar 

  10. Grizzi F, Chiriva-Internati M (2006) Cancer: looking for simplicity and finding complexity. Cancer Cell Int 6:4

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sell S, Nicolini A, Ferrari P, Biava PM (2016) Cancer: a problem of developmental biology; scientific evidence for reprogramming and differentiation therapy. Curr Drug Targets 17(10):1103–1110

    Article  CAS  PubMed  Google Scholar 

  12. Segal NH, Pavlidis P, Antonescu CR et al (2003) Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163(2):691–700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Strong LC, Williams WR, Tainsky MA (1992) The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 135(2):190–199

    Article  CAS  PubMed  Google Scholar 

  14. Stratton MR, Moss S, Warren W et al (1990) Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5(9):1297–1301

    CAS  PubMed  Google Scholar 

  15. Kruzelock RP, Hansen MF (1995) Molecular genetics and cytogenetics of sarcomas. Hematol Oncol Clin North Am 9(3):513–540

    Article  CAS  PubMed  Google Scholar 

  16. Skapek SX, Chui CH (2000) Cytogenetics and the biologic basis of sarcomas. Curr Opin Oncol 12(4):315–322

    Article  CAS  PubMed  Google Scholar 

  17. Karpeh MS, Brennan MF, Cance WG et al (1995) Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 72(4):986–991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Xiao X, Garbutt CC, Hornicek F et al (2018) Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. Cancer Treat Rev 63:61–70

    Article  CAS  PubMed  Google Scholar 

  19. Jones KB (2018) What’s in a name? Cell fate reprogramming in sarcomagenesis. Cancer Cell 33(1):5–7

    Article  CAS  PubMed  Google Scholar 

  20. Drummond CJ, Hanna JA, Garcia MR et al (2018) Hedgehog pathway drives fusionnegative rhabdomyosarcoma initiated from non-myogenic endothelial progenitors. Cancer Cell 33(1):108–124.e5

    Article  CAS  PubMed  Google Scholar 

  21. Oda Y, Yamamoto H, Kohashi K et al (2017) Soft tissue sarcomas: from a morphological to a molecular biological approach. Pathol Int 67(9):435–446

    Article  CAS  PubMed  Google Scholar 

  22. Hamacher R, Bauer S (2017) Preclinical models for translational sarcoma research. Curr Opin Oncol 29(4):275–285

    Article  CAS  PubMed  Google Scholar 

  23. Ramón y Cajal S, Castellvi J, Hümmer S et al (2018) Beyond molecular tumor heterogeneity: protein synthesis takes control. Oncogene 37(19):2490–2501

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chowell D, Napier J, Gupta R et al (2018) Modeling the subclonal evolution of cancer cell populations. Cancer Res 78(3):830–839

    Article  CAS  PubMed  Google Scholar 

  25. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481(7381):306–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Osman S, Lehnert BE, Elojeimy S et al (2013) A comprehensive review of the retro-peritoneal anatomy, neoplasms, and pattern of disease spread. Curr Probl Diagn Radiol 42(5):191–208

    Article  PubMed  Google Scholar 

  27. Loewenstein S, Lubezky N, Nizri E et al (2016) Adipose-induced retroperitoneal soft tissue sarcoma tumorigenesis: a potential crosstalk between sarcoma and fat cells. Mol Cancer Res 14(12):1254–1265

    Article  CAS  PubMed  Google Scholar 

  28. Grizzi F, Chiriva-Internati M (2005) The complexity of anatomical systems. Theor Biol Med Model 2:26

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ogino J, Asanuma H, Hatanaka Y et al (2013) Validity and reproducibility of Ki-67 assessment in gastrointestinal stromal tumors and leiomyosarcomas. Pathol Int 63(2):102–107

    Article  PubMed  Google Scholar 

  30. Ehnman M, Larsson O (2015) Microenvironmental targets in sarcoma. Front Oncol 5:248

    Article  PubMed  PubMed Central  Google Scholar 

  31. Tomlinson J, Barsky SH, Nelson S et al (1999) Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 5(11):3516–3522

    CAS  PubMed  Google Scholar 

  32. West CC, Brown NJ, Mangham DC et al (2005) Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol 31(10):1198–1205

    Article  CAS  PubMed  Google Scholar 

  33. D’Angelo SP, Shoushtari AN, Agaram NP et al (2015) Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46(3):357–365

    Article  PubMed  Google Scholar 

  34. Berghuis D, Santos SJ, Baelde HJ et al (2011) Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 223(3):347–357

    Article  CAS  PubMed  Google Scholar 

  35. Sorbye SW, Kilvaer T, Valkov A et al (2011) Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 6(1):e14611

    Article  PubMed  PubMed Central  Google Scholar 

  36. Tseng WW, Demicco EG, Lazar AJ et al (2012) Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications. Am J Surg Pathol 36(6):941–944

    Article  PubMed  Google Scholar 

  37. Blees A, Januliene D, Hofmann T et al (2017) Structure of the human MHC-I peptideloading complex. Nature 551(7681):525–528

    CAS  PubMed  Google Scholar 

  38. Berghuis D, de Hooge AS, Santos SJ et al (2009) Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 218(2):222–231

    Article  CAS  PubMed  Google Scholar 

  39. Garcia-Lora A, Martinez M, Algarra I et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106(4):521–527

    Article  CAS  PubMed  Google Scholar 

  40. Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998

    Article  CAS  PubMed  Google Scholar 

  41. Leone P, Shin EC, Perosa F et al (2013) MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 105(16):1172–1187

    Article  CAS  PubMed  Google Scholar 

  42. Bukur J, Jasinski S, Seliger B (2012) The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22(4):350–358

    Article  CAS  PubMed  Google Scholar 

  43. del Campo AB, Carretero J, Aptsiauri N, Garrido F (2012) Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79(3):147–154

    Article  PubMed  Google Scholar 

  44. Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118(1):129–138

    Article  CAS  PubMed  Google Scholar 

  45. Heemels MT, Ploegh H (1995) Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64:463–491

    Article  CAS  PubMed  Google Scholar 

  46. Ortmann B, Copeman J, Lehner PJ et al (1997) A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 277(5330):1306–1309

    Article  CAS  PubMed  Google Scholar 

  47. Lehner PJ, Surman MJ, Cresswell P (1998) Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220. Immunity 8(2):221–231

    Article  CAS  PubMed  Google Scholar 

  48. Pamer E, Cresswell P (1998) Mechanisms of MHC class I–restricted antigen processing. Annu Rev Immunol 16:323–358

    Article  CAS  PubMed  Google Scholar 

  49. Peh CA, Burrows SR, Barnden M et al (1998) HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 8(5):531–542

    Article  CAS  PubMed  Google Scholar 

  50. Barnden MJ, Purcell AW, Gorman JJ, McCluskey J (2000) Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J Immunol 165(1):322–330

    Article  CAS  PubMed  Google Scholar 

  51. Garbi N, Tan P, Diehl AD et al (2000) Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 1(3):234–238

    Article  CAS  PubMed  Google Scholar 

  52. Grandea AG 3rd, Golovina TN, Hamilton SE et al (2000) Impaired assembly yet normal trafficking of MHC class I molecules in tapasin mutant mice. Immunity 13(2):213–222

    Article  CAS  PubMed  Google Scholar 

  53. Purcell AW, Gorman JJ, Garcia-Peydro M et al (2001) Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 166(2):1016–1027

    Article  CAS  PubMed  Google Scholar 

  54. Ogino T, Bandoh N, Hayashi T et al (2003) Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9(11):4043–4051

    CAS  PubMed  Google Scholar 

  55. Anichini A, Mortarini R, Nonaka D et al (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66(12):6405–6411

    Article  CAS  PubMed  Google Scholar 

  56. Liu Y, Komohara Y, Domenick N et al (2012) Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother 61(6):789–801

    Article  CAS  PubMed  Google Scholar 

  57. Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57(11):1719–1726

    Article  CAS  PubMed  Google Scholar 

  58. Ogino T, Shigyo H, Ishii H et al (2006) HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66(18):9281–9289

    Article  CAS  PubMed  Google Scholar 

  59. Campoli M, Chang CC, Ferrone S (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20(Suppl 4):A40–A45

    Article  CAS  PubMed  Google Scholar 

  60. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12(1):3–13

    Article  CAS  PubMed  Google Scholar 

  61. Chang CC, Campoli M, Ferrone S (2003) HLA class I defects in malignant lesions: what have we learned? Keio J Med 52(4):220–229

    Article  CAS  PubMed  Google Scholar 

  62. Atkins D, Ferrone S, Schmahl GE et al (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171(2 Pt 1):885–889

    Article  CAS  PubMed  Google Scholar 

  63. Campoli M, Chang CC, Oldford SA et al (2004) HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 20:105–125

    Article  CAS  PubMed  Google Scholar 

  64. Facoetti A, Nano R, Zelini P et al (2005) Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11(23):8304–8311

    Article  CAS  PubMed  Google Scholar 

  65. Ferris RL, Hunt JL, Ferrone S (2005) Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33(2):113–133

    Article  CAS  PubMed  Google Scholar 

  66. Kloor M, Becker C, Benner A et al (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65(14):6418–6424

    Article  CAS  PubMed  Google Scholar 

  67. Meissner M, Reichert TE, Kunkel M et al (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11(7):2552–2560

    Article  CAS  PubMed  Google Scholar 

  68. Raffaghello L, Prigione I, Bocca P et al (2005) Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24(29):4634–4644

    Article  CAS  PubMed  Google Scholar 

  69. Vitale M, Pelusi G, Taroni B et al (2005) HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 11(1):67–72

    CAS  PubMed  Google Scholar 

  70. Bangia N, Ferrone S (2006) Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest 35(3– 4):485–503

    Article  CAS  PubMed  Google Scholar 

  71. Chang CC, Ogino T, Mullins DW et al (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281(27):18763–18773

    Article  CAS  PubMed  Google Scholar 

  72. Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12(13):3890–3895

    Article  CAS  PubMed  Google Scholar 

  73. López-Albaitero A, Nayak JV, Ogino T et al (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176(6):3402–3409

    Article  PubMed  Google Scholar 

  74. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56(2):227–236

    Article  CAS  PubMed  Google Scholar 

  75. Seliger B, Stoehr R, Handke D et al (2010) Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 59(4):529–540

    Article  CAS  PubMed  Google Scholar 

  76. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45):5869–5885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. del Campo AB, Kyte JA, Carretero J et al (2014) Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 134(1):102–113

    Article  PubMed  Google Scholar 

  78. Fairweather M, Gonzalez RJ, Strauss D, Raut CP (2018) Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol 117(1):33–41

    Article  PubMed  Google Scholar 

  79. Segal NH, Blachere NE, Guevara-Patiño JA et al (2005) Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 5(1):2

    PubMed  Google Scholar 

  80. Roszik J, Wang WL, Livingston JA et al (2017) Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11

    Article  PubMed  PubMed Central  Google Scholar 

  81. Pollack SM, Ingham M, Spraker MB, Schwartz GK (2018) Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol 36(2):125–135

    Article  PubMed  Google Scholar 

  82. Salmaninejad A, Zamani MR, Pourvahedi M et al (2016) Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest 45(7):619–640

    Article  CAS  PubMed  Google Scholar 

  83. Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W (2004) Cancer immunotherapy: avoiding the road to perdition. J Transl Med 2(1):26

    Article  PubMed  PubMed Central  Google Scholar 

  84. Iura K, Maekawa A, Kohashi K et al (2017) Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 61:130–139

    Article  CAS  PubMed  Google Scholar 

  85. Iura K, Kohashi K, Hotokebuchi Y et al (2015) Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 1(3):144–159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Iura K, Kohashi K, Ishii T et al (2017) MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. Virchows Arch 471(3):383–392

    Article  CAS  PubMed  Google Scholar 

  87. Groisberg R, Hong DS, Behrang A et al (2017) Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100

    Article  PubMed  PubMed Central  Google Scholar 

  88. Zheng B, Ren T, Huang Y, Guo W (2018) Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun 495(2):1695–1701

    Article  CAS  PubMed  Google Scholar 

  89. Machado I, López-Guerrero JA, Scotlandi K et al (2018) Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT). Virchows Arch 472(5):815–824

    Article  CAS  PubMed  Google Scholar 

  90. Boxberg M, Steiger K, Lenze U et al (2018) PD-L1 and PD-1 and characterization of tumorinfiltrating lymphocytes in high grade sarcomas of soft tissue — prognostic implications and rationale for immunotherapy. Oncoimmunology 7(3):e1389366

    Article  PubMed  Google Scholar 

  91. Zhu Z, Jin Z, Zhang M et al (2017) Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Oncotarget 8(35):59570–59580

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Inflammation, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

    Fabio Grizzi

Authors
  1. Fabio Grizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Monica Borroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dorina Qehajaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sanja Stifter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maurizio Chiriva-Internati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ferdinando C. M. Cananzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabio Grizzi .

Editor information

Editors and Affiliations

  1. Surgical Oncology Unit, Department of Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

    Vittorio Quagliuolo

  2. Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Alessandro Gronchi

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag Italia

About this chapter

Cite this chapter

Grizzi, F., Borroni, E.M., Qehajaj, D., Stifter, S., Chiriva-Internati, M., Cananzi, F.C.M. (2019). The Complex Nature of Soft Tissue Sarcomas, Including Retroperitoneal Sarcomas. In: Quagliuolo, V., Gronchi, A. (eds) Current Treatment of Retroperitoneal Sarcomas. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-3980-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-3980-3_3

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-3979-7

  • Online ISBN: 978-88-470-3980-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation